Pharmacolog i Uppsala (PERP-B.ST) Stock Analysis & AI Equity Report
Pharmacolog i Uppsala (PERP-B.ST) overview
Pharmacolog i Uppsala (PERP-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Pharmacolog i Uppsala reported revenue of SEK 14.6m and operating profit of SEK 2.0m; the year-end share price was 5.30 SEK and market capitalisation was SEK 24.7m. Pharmacolog i Uppsala is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pharmacolog i Uppsala's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Pharmacolog i Uppsala
Pharmacolog i Uppsala AB develops medical technology for the preparation and verification of injectable drugs. Its products, including DrugLog, WasteLog and PrepLog, are used in pharmacies, hospital wards and surgical settings to reduce medication errors, support compounding quality and help detect possible tampering or diversion of controlled substances.
Generate the Pharmacolog i Uppsala report
Pharmacolog i Uppsala is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pharmacolog i Uppsala and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.